Moreover, the therapeutic effects of palbociclib have been demonstrated in numerous clinical trials for breast cancer, NSCLC, Goodpasture’s Syndrome, lymphoma and leukemia, in combination with 5-FU and oxaliplatin in solid malignancies (NCT01522989) or with cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), in HNSCC [138,139]. This evidence concerns the gene EGFR and lymphoma.